Curr Pharm Biotechnol. 2007 Dec;8(6):401-11.

Epigenetic targeting in acute myeloid leukemia: use of flow cytometry in monitoring therapeutic effects.

Ryningen A, Bruserud Ø.

Curr Pharm Biotechnol. 2007 Dec;8(6):344-54.

Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in acute myeloid leukemia.

Oyan AM, Bø TH, Jonassen I, Ulvestad E, Tore Gjertsen B, Bruserud O, Kalland KH.

Curr Pharm Biotechnol. 2007 Dec;8(6):318-9.

Introduction: RNA and the treatment of human cancer.

Bruserud O.

Int J Oncol. 2007 Dec;31(6):1529-38.

Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors.

Stapnes C, Ryningen A, Hatfield K, Øyan AM, Eide GE, Corbascio M, Kalland KH, Gjertsen BT, Bruserud Ø.

Expert Opin Ther Targets. 2007 Aug;11(8):1055-69.

Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling.

Hagland H, Nikolaisen J, Hodneland LI, Gjertsen BT, Bruserud Ø, Tronstad KJ.

Eur J Haematol. 2007 Sep;79(3):210-25. Epub 2007 Jul 26.

Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.

Ersvaer E, Zhang JY, McCormack E, Olsnes A, Anensen N, Tan EM, Gjertsen BT, Bruserud O.

Hematology. 2007 Jun;12(3):199-207.

Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex.

Ersvaer E, Hampson P, Wendelbo Ø, Lord JM, Gjertsen BT, Bruserud Ø.

Mol Cancer. 2007 May 11;6:33.

Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.

Wergeland L, Sjøholt G, Haaland I, Hovland R, Bruserud Ø, Gjertsen BT.

Expert Rev Anticancer Ther. 2007 May;7(5):741-51.

Early gene expression of acute myeloid leukemia in response to chemotherapy.

Anensen N, Øyan AM, Huseby S, Kalland KH, Bruserud Ø, Gjertsen BT.

Mol Cancer. 2007 Apr 23;6:31.

LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.

Huang TS, Myklebust LM, Kjarland E, Gjertsen BT, Pendino F, Bruserud Ø, Døskeland SO, Lillehaug JR.

Anal Biochem. 2007 Jul 1;366(1):46-58. Epub 2007 Mar 18.

Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization.

Petersen K, Oyan AM, Rostad K, Olsen S, Bø TH, Salvesen HB, Gjertsen BT, Bruserud O, Halvorsen OJ, Akslen LA, Steen VM, Jonassen I, Kalland KH.

Leuk Res. 2007 Sep;31(9):1303-13. Epub 2007 Apr 9.

Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.

Ryningen A, Stapnes C, Bruserud Ø.

Transfusion. 2007 Apr;47(4):653-65.

In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.

Apelseth TØ, Bruserud Ø, Wentzel-Larsen T, Bakken AM, Bjørsvik S, Hervig T.

Br J Haematol. 2007 Mar;136(6):814-28.

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.

Stapnes C, Døskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB, Gjertsen BT, Bruserud O.

Haematologica. 2007 Mar;92(3):332-41.

Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.

Bruserud Ø, Ryningen A, Olsnes AM, Stordrange L, Øyan AM, Kalland KH, Gjertsen BT.

Cancer Immunol Immunother. 2007 Jun;56(6):913-25. Epub 2006 Nov 8.

T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005.

Ersvaer E, Hampson P, Hatfield K, Ulvestad E, Wendelbo Ø, Lord JM, Gjertsen BT, Bruserud Ø.

Blood. 2007 Mar 15;109(6):2589-96. Epub 2006 Nov 14.

Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.

Irish JM, Anensen N, Hovland R, Skavland J, Børresen-Dale AL, Bruserud O, Nolan GP, Gjertsen BT.

Cancer Immunol Immunother. 2007 Jan;56(1):13-24. Epub 2006 Apr 13.

Effects of interferon gamma on native human acute myelogenous leukaemia cells.

Ersvaer E, Skavland J, Ulvestad E, Gjertsen BT, Bruserud Ø.